Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
“In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
- “In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
- We believe this mechanism explains the strong clinical results we have seen in both our Phase 1b/2 and ONSEMBLE second-line RAS-mutated mCRC clinical trials.
- The abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
- Following presentation, the posters will be posted to the " Scientific Presentations " section of the Cardiff Oncology website.